Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.

Related articles
Lp(a) as ASCVD risk factor
  • Dyslipidemia
  • Dyslipidemia

Lp(a) as ASCVD risk factor

Read article
Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
  • Dyslipidemia
  • Dyslipidemia

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Read article
The role of the patient in Achieving LDL-C Target
  • Dyslipidemia
  • Cardiovascular
  • Dyslipidemia

The role of the patient in Achieving LDL-C Target

Read article
MAT-BH-2200017/v2/Jun 2023